设为首页加入收藏
  • 首页
  • Start up
  • 当前位置:首页 >Start up >【】

    【】

    发布时间:2025-09-15 08:43:38 来源:都市天下脉观察 作者:Start up

    Latest

    AI

    Amazon

    Apps

    Biotech & Health

    Climate

    Cloud Computing

    Commerce

    Crypto

    Enterprise

    EVs

    Fintech

    Fundraising

    Gadgets

    Gaming

    Google

    Government & Policy

    Hardware

    Instagram

    Layoffs

    Media & Entertainment

    Meta

    Microsoft

    Privacy

    Robotics

    Security

    Social

    Space

    Startups

    TikTok

    Transportation

    Venture

    More from TechCrunch

    Staff

    Events

    Startup Battlefield

    StrictlyVC

    Newsletters

    Podcasts

    Videos

    Partner Content

    TechCrunch Brand Studio

    Crunchboard

    Contact Us

    In Brief

    Posted:

    5:19 PM PST · January 27, 2025
    Reid Hoffman
    Image Credits:David Paul Morris/Bloomberg / Getty Images
    • Marina Temkin
    • Marina Temkin

    Reid Hoffman’s Manas AI raises $24.6M, a fraction of other AI drug discovery startups

    LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book “The Emperor of All Maladies,” have co-founded an AI-powered drug discovery startup, Manas AI. The company, which will initially focus on breast cancer, prostate cancer, and lymphoma, has raised $24.6 million in seed funding from Hoffman, General Catalyst, and Greylock.

    Manas AI’s capital haul pales compared with some other startups trying to use AI models to develop novel drugs. Last year, Xaira, which claimed that it was ready to start developing drugs, launched with a massive $1 billion in initial funding. Treeline Biosciences is another company that uses AI for drug discovery and raised $422 million last year,  Endpts reported.

    Manas AI claims it will design molecules with AI, then test them in a wet lab, Hoffman reportedly said during the presentation of his new book “Superagency.” The outfit also says it will use Microsoft’s cloud computing platform, Azure, and Microsoft’s “deep domain knowledge in AI” to develop novel medicines.

    Hoffman has close ties to Microsoft, which famously acquired his earlier company, LinkedIn, in a blockbuster deal in 2016.

    • 上一篇:Retirable secures $6M to plan retirement for those without millions in savings
    • 下一篇:Gourmey grabs $48 million to keep working on lab

      相关文章

      • 8 investors weigh in on the state of insurtech in Q3 2022
      • 3 views: Predicting 2023's key startup themes
      • Pangea Cyber wants to simplify security for developers with an API approach
      • Egypt's SideUp raises $1.2M to grow its e
      • Indian market regulator tightens IPO disclosure norms
      • A tool for analyzing face
      • How Up.Labs threads the needle between corporate venture capital and accelerators
      • Komi, a landing page tool for content creators, raises $5M seed round
      • Party Round's rebrand is banking on founder bank accounts
      • Dat Bike gets another $8M to put more e

        随便看看

      • With new cuts, Klarna joins the ranks of companies having to conduct more than one layoff
      • Cofactr: Logistics and procurement on autopilot
      • AirTree and Greycroft return to lead Australian regtech FrankieOne’s Series A+
      • How to run data on Kubernetes: 6 starting principles
      • Q&A: ‘Better Venture’ authors on why VC has failed to reinvent itself
      • Which way is up? The end of free money and the importance of keeping cash on hand
      • Which way is up? The end of free money and the importance of keeping cash on hand
      • Deepomatic wants to build the AI
      • Meet the young turks of blockchain, DeFi and web3 exhibiting at TC Sessions: Crypto
      • #MyTechFrenemy
      • Copyright © 2025 Powered by 【】,都市天下脉观察   辽ICP备198741324484号sitemap